SCHEMBL10109481

SCHEMBL10109481

CC(=O)Oc1ccc2c(c1)C1(C)CCN(C)C1N2C

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE P22303 16/20 0.77
BCHE P06276 11/20 0.77
KDM4E B2RXH2 5/20 0.77
ALDH1A1 P00352 3/20 0.77
CYP2D6 P10635 2/20 0.77
SMN1; SMN2 Q16637 2/20 0.77
MEN1 O00255 1/20 0.77
CYP1A2 P05177 1/20 0.77
KMT2A Q03164 1/20 0.77
HIF1A Q16665 1/20 0.77
LMNA P02545 1/20 0.77
PTGS1 P23219 1/20 0.77
OPRM1 P35372 1/20 0.77
OPRK1 P41145 1/20 0.77
BLM P54132 1/20 0.77
HRH3 Q9Y5N1 1/20 0.77
HSD17B10 Q99714 1/20 0.71
NPC1 O15118 1/20 0.70
MAPT P10636 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8199132 0.93 ACHE (0.77) ACHEBCHEKDM4EALDH1A1CYP2D6
SCHEMBL9204867 0.93 ACHE (0.77) ACHEBCHEKDM4EALDH1A1CYP2D6
SCHEMBL9204862 0.93 ACHE (0.77) ACHEBCHEKDM4EALDH1A1CYP2D6
SCHEMBL9204860 0.91 ACHE (0.79) ACHEBCHEKDM4EALDH1A1CYP2D6
SCHEMBL9206918 0.89 ACHE (0.79) ACHEBCHEKDM4EALDH1A1CYP2D6
SCHEMBL9206926 0.89 ACHE (0.79) ACHEBCHEKDM4EALDH1A1CYP2D6
SCHEMBL9206921 0.89 ACHE (0.79) ACHEBCHEKDM4EALDH1A1CYP2D6
Fumaric Acid SCHEMBL9208733 0.88 KDM4E (0.72) ACHEBCHEKDM4EALDH1A1CYP2D6
Fumaric Acid SCHEMBL9208758 0.88 KDM4E (0.72) ACHEBCHEKDM4EALDH1A1CYP2D6
Physostigmine SCHEMBL13930339 0.87 ACHE (1.00) ACHEBCHEKDM4EALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101782-B2 Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory COLUCID PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20080261950-A1 Compounds that inhibit cholinesterase COLUCID PHARMACEUTICALS, INC. (US) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261950-A1 Compounds that inhibit cholinesterase ACHE, BCHE, CHAT ACHE 1/4885BCHE 2/4885KDM4E 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.